Spdr Sp Pharmaceuticals Etf Profile

XPH Etf  USD 46.19  0.09  0.19%   

Performance

6 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 34

 
High
 
Low
Below Average
SPDR SP is trading at 46.19 as of the 30th of November 2024. This is a 0.19 percent decrease since the beginning of the trading day. The etf's open price was 46.28. SPDR SP has about a 34 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for SPDR SP Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
In seeking to track the performance of the SP Pharmaceuticals Select Industry Index , the fund employs a sampling strategy. SP Pharmaceuticals is traded on NYSEARCA Exchange in the United States. More on SPDR SP Pharmaceuticals

Moving against SPDR Etf

  0.64IHF iShares HealthcarePairCorr
  0.59IXJ iShares Global HealthcarePairCorr
  0.54XLV Health Care SelectPairCorr
  0.53IYH iShares Healthcare ETFPairCorr
  0.47VHT Vanguard Health CarePairCorr
  0.47FHLC Fidelity MSCI HealthPairCorr

SPDR Etf Highlights

Vice PresidentMichael Riley
Thematic Ideas
(View all Themes)
Old Names[Hanoi Soap JSC, Ssga Spdr Pharmaceuticals]
Business ConcentrationSector ETFs, Health Care ETFs, Health, SPDR State Street Global Advisors (View all Sectors)
IssuerSSgA
Inception Date2006-06-19
BenchmarkS&P Pharmaceuticals Index
Entity TypeRegulated Investment Company
Asset Under Management164.49 Million
Average Trading Valume66,915.9
Asset TypeEquity
CategorySector
FocusHealth Care
Market ConcentrationDeveloped Markets
RegionNorth America
AdministratorSSgA Funds Management, Inc.
AdvisorSSgA Funds Management, Inc.
CustodianState Street Bank and Trust Company
DistributorState Street Global Advisors Funds Distributors, LLC
Portfolio ManagerMichael Feehily, Karl Schneider, Keith Richardson
Transfer AgentState Street Bank and Trust Company
Fiscal Year End30-Jun
ExchangeNYSE Arca, Inc.
Number of Constituents52.0
Market MakerCitadel
Total Expense0.35
Management Fee0.35
Country NameUSA
Returns Y T D12.58
NameSPDR SP Pharmaceuticals ETF
Currency CodeUSD
Open FigiBBG000D73SW9
In Threey Volatility18.08
1y Volatility18.49
200 Day M A42.8873
50 Day M A45.6756
CodeXPH
Updated At30th of November 2024
Currency NameUS Dollar
SPDR SP Pharmaceuticals [XPH] is traded in USA and was established 2006-06-19. The fund is classified under Health category within SPDR State Street Global Advisors family. The entity is thematically classified as Sector ETFs. SPDR SP Pharmaceuticals at this time have 206.63 M in net assets. , while the total return for the last 3 years was 0.9%.
Check SPDR SP Probability Of Bankruptcy

Geographic Allocation (%)

Top SPDR SP Pharmaceuticals Etf Constituents

MNKMallinckrodt PlcStockHealth Care
MRKMerck CompanyStockHealth Care
ZTSZoetis IncStockHealth Care
VTRSViatrisStockHealth Care
SAVACassava SciencesStockHealth Care
RPRXRoyalty Pharma PlcStockHealth Care
RETAReata PharmaceuticalsStockHealth Care
PRGOPerrigo Company PLCStockHealth Care
More Details

SPDR SP Top Holders

NAVFXThe Sector RotationMutual FundLarge Growth
PILLDirexion Daily PharmaceuticalEtfTrading--Leveraged Equity
CAPTXCanterbury Portfolio ThermostatMutual FundTactical Allocation
LCAIXLazard Capital AllocatorMutual FundTactical Allocation
LCAOXLazard Capital AllocatorMutual FundTactical Allocation
More Details

SPDR SP Pharmaceuticals Risk Profiles

The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in SPDR SP. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.

SPDR SP Against Markets

When determining whether SPDR SP Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SPDR SP's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spdr Sp Pharmaceuticals Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Spdr Sp Pharmaceuticals Etf:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in SPDR SP Pharmaceuticals. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
The market value of SPDR SP Pharmaceuticals is measured differently than its book value, which is the value of SPDR that is recorded on the company's balance sheet. Investors also form their own opinion of SPDR SP's value that differs from its market value or its book value, called intrinsic value, which is SPDR SP's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SPDR SP's market value can be influenced by many factors that don't directly affect SPDR SP's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.